BioPharma Credit PLC
BOPCFOTCFinancial Services● Active
$0.91
+$0.91(+82064.72%)
Market Cap$1.0B
P/E Ratio—
52W High$1.02
52W Low$0.8364
BioPharma Credit PLC（BOPCF）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BOPCF · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.13B | $0.12B | $0.11B | $0.18B | $0.08B |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($0.02B) | ($0.01B) | ($0.01B) | $0.01B | ($0.01B) |
| Net Cash from Operations | $0.09B | $0.11B | $0.12B | $0.18B | $0.10B |
| Investing Activities | |||||
| Capital Expenditure | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Purchases of Investments | ($0.08B) | $0.00B | ($0.04B) | ($0.10B) | ($0.19B) |
| Sales of Investments | $0.16B | $0.04B | $0.04B | $0.15B | $0.09B |
| Net Cash from Investing | $0.08B | $0.04B | ($0.00B) | $0.05B | ($0.09B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.05B) | ($0.11B) | ($0.02B) | ($0.05B) | $0.00B |
| Dividends Paid | ($0.11B) | ($0.17B) | ($0.09B) | ($0.16B) | ($0.10B) |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($0.16B) | ($0.28B) | ($0.11B) | ($0.21B) | ($0.10B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.09B | $0.11B | $0.12B | $0.18B | $0.10B |
| FCF Margin %(computed) | 64.96% | 89.92% | 90.75% | 100.02% | 109.62% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解BioPharma Credit PLC
关于BioPharma Credit PLC（BOPCF）现金流量表
BioPharma Credit PLC 2025财年经营活动现金流$0.09B，自由现金流$0.09B（FCF利润率64.96%），资本支出$0.00B。
常见问题
BOPCF · 4 问BioPharma Credit PLC 2025财年自由现金流$0.09B，同比down18.6%。
BOPCF free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10